Podravka Group business results for 1-6 2026 period

23rd July 2026

Podravka
GRUPA

Podravka Group operating revenues by segments



Podravka Group in 1 – 6 2026[1]:

- **Own brands** → 1.9% higher sales revenues,
- **Other sales** → 1.0% higher sales revenues,
- **Other operating revenues[2]** → 6.7% higher revenues,
- **Total Podravka Group** → 1.7% higher revenues.

Food segment in 1 – 6 2026[1]:

- **Own brands** → 1.5% higher sales, primarily due to higher sales in the markets of Croatia, Southeastern and Western Europe,
- **Other sales** → (2.3%) lower sales, attributable to lower sales of grain commodities,
- **Total Food** → 1.1% higher sales revenues.

Pharmaceuticals segment in 1 – 6 2026[1]:

- **Own brands** → 5.8% higher sales, primarily in the categories of OTC drugs and Nervous system drugs in the markets of Eastern Europe and Croatia,
- **Other sales** → 16.2% higher revenues, primarily due to higher sales of trade goods in the market of Bosnia and Herzegovina,
- **Total Pharma** → 7.1% higher sales revenues.

Agri segment in 1 – 6 2026[1]:

- **Own brands** → 0.3% higher sales revenues,
- **Other sales** → (12.2%) lower sales revenues,
- **Other operating revenues[2]** → relates to revenues from incentives in agriculture and is higher by 6.7%,
- **Total Agri** → 0.5% higher sales revenues.

[1]Data refers to performance in 1-6 2026 compared to 1-6 2025 pro-forma result of the Podravka Group. The pro forma result of the Podravka Group for 2025 represents a simulated consolidated operating result of the Group prepared to present it on a comparable (like-for-like) basis with the Group's results for 2026. The pro forma presentation includes the result of the Agri segment for January 2025 so that the effect of the acquisition is included for the entire comparative period, even though the acquisition was completed on January 31, 2025. For the sake of comparability, revenues from the sale of the confectionery assortment of Šumi Gorenjka d.o.o., which in 2025 were recorded within the revenues of own brands, are classified under Other sales in all observed periods, in accordance with the method of recording after the change of ownership of the company. Additionally, in the pro forma presentation, for comparability purposes, the pro forma presentation also excludes the operations of Deltis Pharm Pharmacies, as this business is no longer part of the Group in 2026.
[2]Other operating revenues refer to agricultural subsidies, which the Podravka Group considers to be regular operating revenues within Agri segment.

Note: The Group's revenues are adjusted for the elimination of intersegmental transactions (consolidation adjustment) between the Food and Agri segments

Operating revenues by business programs, categories and sub-segments

Realization of business programs, categories and sub-segments in 1 – 6 2026.[1]:

- **BU Culinary (-2.4%)** → EUR 1.5m lower sales than in the comparative period, where the decline in revenue was primarily recorded in the U.S. market, which was negatively impacted by movements in the U.S. dollar exchange rate, as well as in Central European markets affected by adverse macroeconomic instabilities,
- **BU Soups (+2.0%)** → EUR 0.6m sales growth. The markets of Kosovo and Croatia contribute most to the growth. The Noodles and Clear soups subcategories contribute most to a positive trend within the Soups business unit,
- **BU Cereals, sweet products & snack (-0.2%)** → sales revenue at almost the same level as in the previous year. Within this, Creamy spreads and desserts achieved revenue growth of EUR 0.4m (+1.9%), primarily driven by the Central European markets, while Cereals, snacks and beverages recorded EUR 0.5m lower revenue (-1.9%) due to different sales activity dynamics compared to the previous year in the Cereals subcategory in the Slovenian market,
- **BU Bakery (+5.8%)** → revenue increase of EUR 1.9m, primarily in the markets of Croatia, Slovenia, Italy and Switzerland. Subcategories Pastry, Bread, but also Cakes and biscuit cakes and Sweet bakery snack contribute most to the revenue growth,
- **BU Fruits, vegetables and sides (+2.2%)** → EUR 1.3m higher revenues. Revenue growth was primarily driven by the Basic food category, mainly in the Czech and Croatian markets, with the largest contribution coming from the Rice and Frozen food subcategories. Within the Fruits and vegetables category, the positive trend was mainly supported by the Condiments and Vegetables subcategories in the Serbian market,
- **BU Meat and fish (+5.2%)** → EUR 1.8m higher sales compared to the comparative period. Revenue growth was primarily driven by the Croatian and Serbian markets within the Fish category, with the positive trend mainly supported by the Canned fish subcategory, while the Meat products category recorded lower revenue, primarily in the markets of Switzerland and the Czech Republic within the Ready meals subcategory,
- **Prescription drugs (+4.2%)** → EUR 2.6m higher revenue compared to the comparative period, primarily driven by higher sales revenue from drugs in the Nervous system and Dermatological drugs categories in the markets of Eastern and Southeastern Europe,
- **Non-prescription program (+13.3%)** → EUR 1.8m higher revenues, as a result of the increase in sales of the OTC drugs category in the markets of Croatia and Eastern Europe,
- **Livestock subsegment (-3.4%)** → EUR 1.9m lower revenue, as a result of lower market prices in pig farming compared to the comparative period,
- **Crop production subsegment (+21.4%)** → EUR 2.3m higher revenues, as a result of improved wheat sales performance,
- **Industrial products subsegment (-0.6%)** → EUR 0.2m lower revenues with dairy products recording higher sales, while the Wine category recorded lower sales compared to the comparative period,
- **Energy and other subsegment (+2.0%)** → which includes biogas plants and smaller subsegments within the Agri segment, recorded EUR 0.2m higher revenue compared to the comparative period,
- **Other sales (+1.0%)** → in the **Food segment**, Other sales decreased by EUR 0.7m (-2.3%), mainly as a result of lower sales of grain commodities. In the **Pharmaceuticals segment**, Other sales recorded EUR 1.9m (+16.2%) higher sales compared to the comparable base, primarily in the market of Bosnia and Herzegovina. In the **Agri segment**, Other sales are EUR 0.7m lower (-12.2%), due to lower sales of trade goods.

Operating revenues by business units, categories and subsegments in 1 - 6 2026



[1]Data refers to performance in 1-6 2026 compared to 1-6 2025 pro-forma result of the Podravka Group. The pro forma result of the Podravka Group for 2025 represents a simulated consolidated operating result of the Group prepared to present it on a comparable (like-for-like) basis with the Group's results for 2026. The pro forma presentation includes the result of the Agri segment for January 2025 so that the effect of the acquisition is included for the entire comparative period, even though the acquisition was completed on January 31, 2025. For the sake of comparability, revenues from the sale of the confectionery assortment of Šumi Gorenjka d.o.o., which in 2025 were recorded within the revenues of own brands, are classified under Other sales in all observed periods, in accordance with the method of recording after the change of ownership of the company. Additionally, in the pro forma presentation, for comparability purposes, the pro forma presentation also excludes the operations of Deltis Pharm Pharmacies, as this business is no longer part of the Group in 2026.

Operating revenues by region



(in EURm)	1 - 6 2025 PF	1 -6 2026	Δ	% change
Markets of Croatia and Slovenia	286.3	290.0	3.8	1.3%
Southeastern Europe	89.5	96.5	6.9	7.7%
Western Europe and Overseas	56.6	55.5	(1.1)	(1.9%)
Central Europe	41.7	39.0	(2.8)	(6.6%)
Eastern Europe	26.2	28.6	2.4	9.3%
Other Operating revenues	14.1	15.1	1.0	6.7%
Consolidation adjustment[2]	(2.5)	(4.0)	(1.6)	
Podravka Group	**512.0**	**520.7**	**8.7**	**1.7%**

Region's performance in 1 – 6 2026.[1]:

- **Markets of Croatia and Slovenia (+1.3%) → the Food segment** achieved EUR 2.0m (+1.4%) higher revenues mainly due to higher sales on the Croatian market in almost all business units. Revenues of the **Pharmaceuticals segment** on the market of Croatia and Slovenia are higher by EUR 1.4m (+4.8%) compared to the comparative period, primarily on OTC drugs. The revenues of **the Agri segment** in the markets of Croatia and Slovenia are EUR 0.4m (+0.4%) higher than in the comparative period,
- **Southeastern Europe (+7.7%) → the Food segment** achieved EUR 2.5m (+4.4%) higher revenue in the markets of Serbia and Bosnia and Herzegovina, primarily in the Canned fish, Condiments and Clear soups subcategories. Higher revenues were achieved despite transport blockades at border crossings at the end of January and regulatory changes in certain Southeast European markets. Revenues in **the Pharmaceuticals segment** were higher by EUR 2.9m (+10.5%) due to growth in Trade goods and Prescription drugs in the market of Bosnia and Herzegovina, while revenues in **the Agri segment** were higher by EUR 1.5m (+36.7%) compared to the comparable base due to higher sales in the markets of Serbia, and Bosnia and Herzegovina,
- **WE and Overseas region (-1.9%) → the Food segment** achieved EUR 0.1m (+0.2%) higher revenue, primarily in the markets of Germany and Austria in the Universal seasonings category. **The Pharmaceuticals segment** achieved revenue growth of EUR 0.1m (+6.3%) primarily in the markets of Great Britain and Germany in the Dermatological drugs category, while **the Agri segment's** revenue was EUR 1.3m (-49.6%) lower compared to the comparable base due to the absence of fattening cattle sales in Lebanon,
- **Central Europe (-6.6%) → the Food segment** recorded a revenue decrease of EUR 1.2m (-3.5%) due to lower sales in the markets of the Czech Republic, Slovakia and Romania, which are characterised by adverse macroeconomic developments and a decline in retail turnover of food and beverages. **The Pharmaceuticals segment** recorded a revenue decrease of EUR 0.6m (-10.0%) due to lower revenues in the market of the Czech Republic following changes to the distribution model, while **the Agri segment's** revenues were lower by EUR 0.9m (-86.8%) compared to the comparable base,
- **Eastern Europe (+9.3%) → the Pharmaceuticals segment** achieved revenue growth of EUR 2.5m (+10.7%), primarily in the Prescription drugs category, while **the Food segment** achieved revenue decline of EUR 0.1m (-2.7%).

[1]Data refers to performance in 1-6 2026 compared to 1-6 2025 pro-forma result of the Podravka Group. The pro forma result of the Podravka Group for 2025 represents a simulated consolidated operating result of the Group prepared to present it on a comparable (like-for-like) basis with the Group's results for 2026. The pro forma presentation includes the result of the Agri segment for January 2025 so that the effect of the acquisition is included for the entire comparative period, even though the acquisition was completed on January 31, 2025. For the sake of comparability, revenues from the sale of the confectionery assortment of Šumi Gorenjka d.o.o., which in 2025 were recorded within the revenues of own brands, are classified under Other sales in all observed periods, in accordance with the method of recording after the change of ownership of the company. Additionally, in the pro forma presentation, for comparability purposes, the pro forma presentation also excludes the operations of Deltis Pharm Pharmacies, as this business is no longer part of the Group in 2026.
[2]The Group's revenues are adjusted for the elimination of intersegmental transactions (consolidation adjustment) between the Food and Agri segments.

Profitability of the Food segment

Food segment	REPORTED				NORMALISED[1]			
(in EURm)	**1 - 6 2025**	**1 - 6 2026**	**Δ**	**%**	**1 - 6 2025**	**1 - 6 2026**	**Δ**	**%**
Sales revenue	295.5	298.9	3.3	1.1%	295.5	298.9	3.3	1.1%
Gross profit	103.7	102.2	(1.4)	(1.4%)	103.7	102.2	(1.5)	(1.4%)
EBITDA	39.6	39.6	0.1	0.1%	39.9	40.0	0.1	0.3%
EBIT	26.3	24.7	(1.5)	(5.9%)	26.6	25.1	(1.5)	(5.6%)
Net profit	16.5	15.6	(1.0)	(5.8%)	16.8	15.9	(0.9)	(5.4%)
Gross margin	35.1%	34.2%		-87 bp	35.1%	34.2%		-89 bp
EBITDA margin	13.4%	13.3%		-13 bp	13.5%	13.4%		-11 bp
EBIT margin	8.9%	8.3%		-61 bp	9.0%	8.4%		-60 bp
Net profit margin	5.6%	5.2%		-38 bp	5.7%	5.3%		-37 bp

Food segment profitability in 1 - 6 2026:

Gross profit

- Decrease in **gross profit** of EUR 1.5m (-1.4%) with a slightly lower gross margin level due to different sales structure,

EBITDA

- **Normalised operating profit before depreciation and amortisation (EBITDA)** is EUR 0.1m (+0,3%) higher, mainly as a result of implemented process improvements aimed at increasing operational efficiency, enhancing the organisation of business processes and better utilisation of available resources

Net profit

- **Normalised net profit** is EUR 0.9m lower (-5.4%) due to higher depreciation and amortisation costs, as the full effect of the completed investment cycle.

[1]Normalized for one-off impact

Profitability of the Pharmaceuticals segment

Pharma segment	REPORTED				NORMALISED[1]			
(in EURm)	1 - 6 2025 PF[2]	1 - 6 2026	Δ	%	1 - 6 2025 PF[2]	1 - 6 2026	Δ	%
Sales revenue	87.7	94.0	6.3	7.1%	87.7	94.0	6.3	7.1%
Gross profit	47.9	51.3	3.4	7.1%	47.9	51.3	3.4	7.1%
EBITDA	25.5	27.1	1.7	6.5%	25.7	27.1	1.5	5.7%
EBIT	21.0	22.6	1.6	7.6%	21.2	22.6	1.4	6.6%
Net profit after MI	16.1	34.9	18.9	117.6%	16.2	18.3	2.0	12.6%
Gross margin	54.6%	54.6%		0 bp	54.6%	54.6%		-2 bp
EBITDA margin	29.0%	28.9%		-17 bp	29.3%	28.9%		-38 bp
EBIT margin	24.0%	24.1%		+10 bp	24.2%	24.1%		-12 bp
Net profit margin after MI	18.3%	37.2%		n/a	18.5%	19.4%		+94 bp

Pharmaceuticals segment profitability in 1 - 6 2026:

Gross profit

- EUR 3.4m (+7.1%) higher **gross profit** as a result of revenue growth while maintaining a high gross margin,

EBITDA

- **Normalised operating profit before depreciation and amortisation (EBITDA)** is EUR 1.5m (+5.7%) higher,

Net profit after MI

- **Normalised net profit after minority interests** amounts to EUR 18.3m and it is EUR 2.0m (+12.6%) higher than the comparable base in 2025 .

[1]Normalized for one-off impact.
[2]The pro forma result of the Pharmaceuticals segment for 2025 represents a simulated result prepared to present on a comparable (like-for-like) basis with the results for 2026. The pro forma result does not include revenues from the sale of trade goods achieved through Deltis Pharm Pharmacies, given that this business is no longer part of the Podravka Group in 2026.

Profitability of the Agri segment

Agri segment	REPORTED				NORMALISED[1]			
(in EURm)	1 - 6 2025 PF[2]	1 - 6 2026	Δ	%	1 - 6 2025 PF[2]	1 - 6 2026	Δ	%
Operating revenues	131.2	131.8	0.6	0.5%	131.2	131.8	0.6	0.5%
Sales revenues	*117.1*	*116.7*	*(0.3)*	*(0.3%)*	*117.1*	*116.7*	*(0.3)*	*(0.3%)*
Other operating revenues[3]	*14.1*	*15.1*	*1.0*	*6.7%*	*14.1*	*15.1*	*1.0*	*6.7%*
Gross profit	25.3	21.6	(3.7)	(14.8%)	25.3	21.6	(3.7)	(14.7%)
EBITDA	80.2	22.5	(57.7)	(71.9%)	25.1	22.5	(2.7)	(10.7%)
EBIT	68.0	10.9	(57.2)	(84.0%)	13.0	10.8	(2.1)	(16.4%)
Net profit	63.7	7.0	(56.7)	(89.1%)	8.4	6.9	(1.5)	(18.1%)
Gross margin	19.3%	16.4%		-292 bp	19.3%	16.4%		-291 bp
EBITDA margin	61.1%	17.1%		n/a	19.2%	17.0%		-213 bp
EBIT margin	51.9%	8.3%		n/a	9.9%	8.2%		-166 bp
Net profit	48.5%	5.3%		n/a	6.4%	5.2%		-119 bp

Agri segment profitability in 1 - 6 2026:

Gross profit

- **Gross profit** lower by EUR 3.7m (-14.8%), primarily as a result of lower market pig prices and lower milk prices,

EBITDA

- The **normalised operating profit before depreciation and amortisation (EBITDA)** in the 1 – 6 2026 period amounts to EUR 22.5m, and is EUR 2.7m (-10.7%) lower than the comparable base in the previous year, with the negative impact of market pig prices of EUR -7.0m and milk prices of EUR -2.2m largely offset through process improvements and changes to the operating model,

Net profit

- **Normalised net profit** amounts to EUR 6.9m and is lower than the comparable base by EUR 1.5m (-18.1%).

[1]Normalized for one-off impact.
[2]Pro forma result of the Agri segment for the period 1-6 2025, simulating the result including January 2025, for the purpose of ensuring comparability..
[3]Other operating income relates to agricultural subsidies, which the Group considers to be regular operating income within the Agri segment.

Profitability of the Podravka Group

Podravka Group	REPORTED					NORMALISED[1]				
(in EURm)	1 - 6 2025[2]	1 - 6 2025 PF[3]	1 - 6 2026	Δ	%	1 - 6 2025[2]	1 - 6 2025 PF[3]	1 - 6 2026	Δ	%
Operating revenues	496.0	512.0	520.7	8.7	1.7%	496.0	512.0	520.7	8.7	1.7%
Sales revenues	*484.0*	*497.9*	*505.6*	*7.7*	*1.5%*	*484.0*	*497.9*	*505.6*	*7.7*	*1.5%*
Other operating revenues	*12.0*	*14.1*	*15.1*	*1.0*	*6.7%*	*12.0*	*14.1*	*15.1*	*1.0*	*6.7%*
Gross profit	174.5	176.4	174.5	(1.9)	(1.1%)	174.5	176.4	174.5	(2.0)	(1.1%)
EBITDA	142.5	145.1	89.3	(55.8)	(38.5%)	88.0	90.5	89.6	(0.9)	(1.0%)
EBIT	114.5	115.2	58.3	(56.9)	(49.4%)	60.0	60.6	58.6	(2.0)	(3.3%)
Net profit after MI	96.0	96.1	57.5	(38.6)	(40.2%)	41.3	41.3	41.1	(0.2)	(0.5%)
Gross margin	35.2%	34.4%	33.5%		-94 bp	35.2%	34.5%	33.5%		-95 bp
EBITDA margin	28.7%	28.3%	17.1%		n/a	17.7%	17.7%	17.2%		-47 bp
EBIT margin	23.1%	22.5%	11.2%		n/a	12.1%	11.8%	11.3%		-58 bp
Net profit margin after MI	19.4%	18.8%	11.0%		-772 bp	8.3%	8.1%	7.9%		-18 bp

Profitability of the Podravka Group in 1 - 6 2026:

Gross profit

- Lower **gross profit** by EUR 1.9m (-1.1%) compared to the comparable base in 2025 with slightly lower gross margin,

EBITDA

- **Normalised operating profit before depreciation and amortisation (EBITDA)** amounts to EUR 89.6m and is lower by EUR 0.9m (-1.0%),

Net profit after MI

- **Normalised net profit after minorities** amounts to EUR 41.1m and is EUR 0.2m (-0.5%) lower than the comparable base in 2025.

[1]Normalized for one-off impact.
[2]Official result of the Podravka Group for the period 1-6 2025, which does not include the result of the Agri segment for January 2025, as ownership of the segment was acquired on 31 January 2025.
[3]The pro forma result of the Podravka Group for 2025 represents a simulated consolidated operating result of the Group prepared to present it on a comparable (like-for-like) basis with the Group's results for 2026. The pro forma presentation includes the result of the Agri segment for January 2025 so that the effect of the acquisition is included for the entire comparative period, even though the acquisition was completed on January 31, 2025. For the sake of comparability, revenues from the sale of the confectionery assortment of Šumi Gorenjka d.o.o., which in 2025 were recorded within the revenues of own brands, are classified under Other sales in all observed periods, in accordance with the method of recording after the change of ownership of the company. Additionally, in the pro forma presentation, for comparability purposes, the pro forma presentation also excludes the operations of Deltis Pharm Pharmacies, as this business is no longer part of the Group in 2026.
Note: The consolidated result of the Podravka Group is presented after the elimination of inter-segment transactions.

Key highlights of the income statement in 1 – 6 2026

Business expenses 1 - 6 26 vs. 1 - 6 25[2] % change	REPORTED		NORMALIZED[1]	
Cost of goods sold (COGS)	7.7%	↑	7.7%	↑
General and administrative expenses (G&A)	5.1%	↑	6.3%	↑
Sales and distribution costs (S&D)	(0.2%)	↓	(0.4%)	↓
Marketing expenses (MEX)	6.7%	↑	6.7%	↑
Other expenses / (revenues), net	(95.6%)	↓	n/a	↑
Total	21.2%	↑	6.0%	↑

Business expenses 1 - 6 26 vs. 1 - 6 25 PF[3] % change	REPORTED		NORMALIZED[1]	
Cost of goods sold (COGS)	3.1%	↑	3.2%	↑
General and administrative expenses (G&A)	2.2%	↑	3.2%	↑
Sales and distribution costs (S&D)	(0.3%)	↓	(0.5%)	↓
Marketing expenses (MEX)	6.3%	↑	6.3%	↑
Other expenses / (revenues), net	(95.5%)	↓	n/a	
Total	16.5%	↑	2.4%	↑

Key highlights of expenses in 1 - 6 2026[3]:

- **Cost of goods sold (COGS):**

Cost of goods sold is EUR 10.6m (+3.1%) higher, whereby in the Food and the Pharmaceuticals segments they are higher as a result of higher sales revenues, while in the Agri segment they are higher as a result of negative movement in market pig prices.

- **General and administrative expenses (G&A):**

General and administrative expenses are slightly higher than in the comparative period, by EUR 0.7m (+2.2%).

- **Sales and distribution costs (S&D):**

In the observed period, selling and distribution costs are EUR 0.2m (-0.3%) lower, which is mainly driven by the Food segment.

- **Marketing expenses (MEX):**

In the reporting period, marketing expenses are EUR 1.8m higher (+6.3%), which primarily arises from the Pharmaceuticals segment, primarily due to an increase in costs of the marketing department following the improved material rights of employees compared to the comparative period. Marketing investment costs also recorded a slight increase in all three observed segments, as a result of different campaign seasonality.

- **Other expenses (revenues), net:**

In the reporting period, other expenses and income, net amounted to EUR -2.5m (positive impact), while in the comparative period they amounted to EUR -55.1m (positive impact), which primarily refers to the recorded difference between the paid compensation and the net acquired assets of the agricultural companies of the Fortenova Group in the amount of EUR 55.04m, which is treated as a one-off item.

[1]Normalized for one-off impact.
[2]Data refers to performance in 1 – 6 2026 compared to the official result of the Podravka Group for the period 1-6 2025, which does not include the result of the Agri segment for January 2025, as ownership of the segment was acquired on 31 January 2025.
[3]Data refers to performance in 1 – 6 2026 compared to the 1 – 6 2025 pro forma (The pro forma result of the Podravka Group for 2025 represents a simulated consolidated operating result of the Group prepared to present it on a comparable (like-for-like) basis with the Group's results for 2026. The pro forma presentation includes the result of the Agri segment for January 2025 so that the effect of the acquisition is included for the entire comparative period, even though the acquisition was completed on January 31, 2025. For the sake of comparability, revenues from the sale of the confectionery assortment of Šumi Gorenjka d.o.o., which in 2025 were recorded within the revenues of own brands, are classified under Other sales in all observed periods, in accordance with the method of recording after the change of ownership of the company. Additionally, in the pro forma presentation, for comparability purposes, the pro forma presentation also excludes the operations of Deltis Pharm Pharmacies, as this business is no longer part of the Group in 2026.

Podravka Group's indebtedness

(in EURm)	2025	1 - 6 2026 [1]	% change
Financial debt[2]	421.7	379.3	(10.1%)
Cash and cash equivalents	40.2	20.2	(49.8%)
Net debt[3]	381.5	359.1	(5.9%)
Interest expense	16.05	14.75	(8.0%)
Net debt / normalized EBITDA	2.27	2.12	(6.8%)
Normalized EBIT / Interest expense	6.8	7.3	7.3%
Equity to total assets ratio	54.8%	57.1%	+232 bp



Key highlights:

- The decrease in net debt as at 30 June 2026 compared to 31 December 2025 is a consequence of the reduction in short-term and long-term debt through regular repayments of borrowings.
- **Net debt/Normalised EBITDA** is 2.12, and the indicator is obtained in a way that income statement items are calculated at the level of the last 12 months, while balance sheet items are taken at the end of the period.
- **Weighted average cost of debt excluding liabilities for right-of-use assets:**
  - As at 30 June 2026 → 3.0%,
  - As at 31 December 2025 → 2.9%.

[1] All indicators were calculated in such a way that the income statement items were calculated at the level of the last 12 months, while the balance sheet items were taken at the end of the period.
[2] Long-term and short-term loans + lease liabilities + financial liabilities at fair value through profit or loss.
[3] Net debt: Financial debt – Cash and cash equivalents.

Key highlights of the cash flow

Working capital movement in BS		30 June 2026 / 31 December 2025	Impact
Inventories	⬇	(5.0%)	• Inventories of the Podravka Group are EUR 12.6m lower than as at 31 December 2025, mainly impacted by the decrease in the inventories of the Agri segment; the inventories of the Food segment are maintained at approximately the same level, while the inventories of the Pharmaceuticals segment are slightly higher,
Trade and other receivables	⬆	6.7%	• Trade and other receivables of the Podravka Group are EUR 13.7m higher than as at 31 December 2025, where this arises equally from all segments and results from regular business developments,
Trade and other payables	⬆	16.2%	• Trade and other payables of the Podravka Group are EUR 23.7m higher compared to the comparable base, and result from regular business developments.

(in EURm)	1 - 6 2025 [1]	1 - 6 2026	Δ
Net cash from operating activities	37.3	41.8	12.0%
Net cash from investing activities	(321.0)	(11.3)	96.5%
Net cash from financing activities	282.5	(50.5)	(117.9%)
Net change of cash and cash equivalents	**(1.3)**	**(20.0)**	**n/a**

- Capital expenditures totalled EUR 22.9m in 2026.



[1]The Podravka Group cash flow statement for 2025 does not include the result of the Agri segment for January, as the segment was acquired on 31 January 2025.

Podravka's share price movement in 1 – 6 2026

PODR share price movement in 1 – 6 2026



Market activity with PODR share

(EUR; units)	1 - 6 2025	1 - 6 2026	% change
Average daily price	142.0	151.7	6.8%
Average daily number of transactions	12	13	13.8%
Average daily volume	604	518	(14.2%)
Average daily turnover	84.348	78.591	(6.8%)
Reported earnings per share	19.2[1]	13.7	(28.6%)
Normalized earnings per share	10.6[1]	10.5	(0.5%)

[1]Based on the results for 2025 [2]Dividend yield calculated based on the last mkt. price at the end of 2025.

Last price on 31 December 2025

150.0 EUR

Last price on 30 June 2026

156.0 EUR

Dividend paid per share

3.20 EUR

Dividend yield[2]

2.1%

Contact

Podravka Inc.

Ante Starčevića 32, 48 000 Koprivnica

https://podravkagrupa.com/en/

Investor Relations

ir@podravka.hr

Podravka Group business results for 1-6 2026 period

23rd July 2026

Podravka
GRUPA